Study of Baricitinib (LY3009104) in Patients With Moderate to Severe Atopic Dermatitis
NCT ID: NCT03334422
Last Updated: 2020-01-22
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
615 participants
INTERVENTIONAL
2017-11-27
2018-12-12
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study of Baricitinib (LY3009104) in Patients With Moderate to Severe Atopic Dermatitis
NCT03334396
A Study of Long-term Baricitinib (LY3009104) Therapy in Atopic Dermatitis
NCT03334435
A Study of Baricitinib (LY3009104) in Adult Participants With Moderate to Severe Atopic Dermatitis
NCT03435081
A Long-term Study of Baricitinib (LY3009104) With Topical Corticosteroids in Adults With Moderate to Severe Atopic Dermatitis That Are Not Controlled With Cyclosporine or for Those Who Cannot Take Oral Cyclosporine Because it is Not Medically Advisable
NCT03428100
A Study of Baricitinib (LY3009104) in Participants With Moderate to Severe Atopic Dermatitis
NCT03559270
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
4 Milligram (mg) Baricitinib
4mg Baricitinib administered orally once daily. Placebo 1 mg and 2 mg administered orally every day to match
Baricitinib
Administered orally
Placebo
Administered orally
2mg Baricitinib
2mg Baricitinib administered orally once daily. Placebo 1 mg and 4 mg administered orally every day to match.
Baricitinib
Administered orally
Placebo
Administered orally
1mg Baricitinib
1mg Baricitinib administered orally once daily. Placebo 2 mg and 4 mg administered orally every day to match.
Baricitinib
Administered orally
Placebo
Administered orally
Placebo
Placebo administered orally once daily.
Placebo
Administered orally
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Baricitinib
Administered orally
Placebo
Administered orally
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Have had inadequate response or intolerance to existing topical (applied to the skin) medications within 6 months preceding screening.
* Are willing to discontinue certain treatments for eczema (such as systemic and topical treatments during a washout period).
* Agree to use emollients daily.
Exclusion Criteria
* A history of eczema herpeticum within 12 months, and/or a history of 2 or more episode of eczema herpeticum in the past.
* Participants who are currently experiencing a skin infection that requires treatment, or is currently being treated, with topical or systemic antibiotics.
* Have any serious illness that is anticipated to require the use of systemic corticosteroids or otherwise interfere with study participation or require active frequent monitoring (e.g., unstable chronic asthma).
* Have been treated with the following therapies:
* Monoclonal antibody for less than 5 half-lives prior to randomization.
* Received prior treatment with any oral Janus kinase (JAK) inhibitor.
* Received any parenteral corticosteroids administered by intramuscular or intravenous (IV) injection within 2 weeks prior to study entry or within 6 weeks prior to planned randomization or are anticipated to require parenteral injection of corticosteroids during the study.
* Have had an intra-articular corticosteroid injection within 2 weeks prior to study entry or within 6 weeks prior to planned randomization.
* Have high blood pressure characterized by a repeated systolic blood pressure \>160 millimeters of mercury (mm Hg) or diastolic blood pressure \>100 mm Hg.
* Have had major surgery within the past eight weeks or are planning major surgery during the study.
* Have experienced any of the following within 12 weeks of screening: venous thromboembolic event (VTE), myocardial infarction (MI), unstable ischemic heart disease, stroke, or New York Heart Association Stage III/IV heart failure.
* Have a history of recurrent (≥ 2) VTE or are considered at high risk of VTE as deemed by the investigator.
* Have a history or presence of cardiovascular, respiratory, hepatic, chronic liver disease gastrointestinal, endocrine, hematological, neurological, lymphoproliferative disease or neuropsychiatric disorders or any other serious and/or unstable illness.
* Have a current or recent clinically serious viral, bacterial, fungal, or parasitic infection including herpes zoster, tuberculosis.
* Have specific laboratory abnormalities.
* Have received certain treatments that are contraindicated.
* Pregnant or breastfeeding.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Incyte Corporation
INDUSTRY
Eli Lilly and Company
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
Role: STUDY_DIRECTOR
Eli Lilly and Company
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
CENIT Centro de Neurociencias, Investigación y Tratamiento
Caba, Buenos Aires, Argentina
Centro de Investigaciones Metabólicas (CINME)
Ciudad Autonoma de Buenos Aire, Buenos Aires, Argentina
Clinica Adventista de Belgrano
Ciudad de Buenos Aires, Buenos Aires, Argentina
Fundacion CIDEA
Buenos Aires, , Argentina
Instituto de Neumonología y Dermatología
Buenos Aires, , Argentina
Psoriahue Medicina Interdisciplinaria
Buenos Aires, , Argentina
Buenos Aires Skin
Ciudad Autonoma Buenos Aires, , Argentina
Parra Dermatología
Mendoza, , Argentina
Woden Dermatology
Phillip, Australian Capital Territory, Australia
Skin & Cancer Foundation Australia
Westmead, New South Wales, Australia
Veracity Clinical Research Pty Ltd
Woolloongabba, Queensland, Australia
Clinical Trials SA Pty Ltd
Adelaide, South Australia, Australia
Skin and Cancer Foundation Inc.
Carlton, Victoria, Australia
Fremantle Dermatology
Perth, Western Australia, Australia
Ordensklinikum Linz GmbH - Elisabethinen
Linz, Upper Austria, Austria
KA Rudolfstiftung
Vienna, , Austria
AKH
Vienna, , Austria
KH Hietzing mit neurologischem Zentrum Rosenhügel
Vienna, , Austria
Sozialmed. Zentrum Ost - Donauspital
Vienna, , Austria
SZTE AOK Borgyogyaszati es Allergologiai Klinika
Szeged, Csongrád megye, Hungary
Debreceni Egyetem Klinikai Kozpont Borgyogyaszati Klinika
Debrecen, Hajdú-Bihar, Hungary
Trial Pharma Kft.
Püspökladány, Hajdú-Bihar, Hungary
Allergo-Derm Bakos Kft
Szolnok, Jász-Nagykun-Szolnok, Hungary
UNO Medical Trials Kft.
Budapest, , Hungary
Kaposi Mor Oktato Korhaz
Kaposvár, , Hungary
Oroshaza Varosi Onkormanyzat Korhaza
Orosháza, , Hungary
Markusovszky Korhaz
Szombathely, , Hungary
MedMare Bt
Veszprém, , Hungary
Haemek Medical Center- Dermatology
Afula, , Israel
Rambam Medical Center
Haifa, , Israel
Hadassah Medical Center - Ein Karem
Jerusalem, , Israel
Rabin Medical Center
Petah Tikva, , Israel
Sheba Medical Center
Ramat Gan, , Israel
Tel Aviv Sourasky Medical Center
Tel Aviv, , Israel
Yanagihara dermatology clinic
Ainokawa, Ichikawa-shi, Chiba, Japan
Kurume University Hospital
Kurume, Fukuoka, Japan
Sapporo Skin Clinic
Sapporo, Hokkaido, Japan
Tokyo Medical University Ibaraki Medical Center
Inashiki-gun, Ibaraki, Japan
Nomura Dermatology Clinic
Yokohama, Kanagawa, Japan
Noguchi Dermatology
Kashima-machi, Kamimashiki-gun, Kumamoto, Japan
Osaka Habikino Medical Center
Habikino, Osaka, Japan
Yoshioka Dermatology Clinic
Neyagawa, Osaka, Japan
Sanrui Dermatology Clinic
Ohmiya-ku,Saitama-shi, Saitama, Japan
Jichi Medical University Hospital
Shimotsuke, Tochigi, Japan
Tokyo Teishin Hospital
Chiyoda-Ku, Tokyo, Japan
Naoko Dermatology Clinic
Setagaya-ku, Tokyo, Japan
Yamate Dermatological Clinic
Shinjuku, Tokyo, Japan
Tachikawa Dermatology Clinic
Tachikawa-shi, Tokyo, Japan
Gifu University Hospital
Gifu, , Japan
Osaka City University Hospital
Osaka, , Japan
NZOZ Specjalistyczna Przychodnia Dermatologiczna Specderm
Bialystok, , Poland
Centrum Badan Klinicznych, PI House
Gdansk, , Poland
Centrum Medyczne Angelius Provita
Katowice, , Poland
Barbara Rewerska DIAMOND CLINIC
Krakow, , Poland
"Dermed" Centrum Medyczne Sp. z o.o.
Lodz, , Poland
Miejski Szpital Zespolony w Olsztynie
Olsztyn, , Poland
DermoDent, Centrum Medyczne Czajkowscy
Osielsko, , Poland
LASER CLINIC S.C. Dr Tomasz Kochanowski, Dr Andrzej Krolicki
Szczecin, , Poland
Centralny Szpital Kliniczny MSW
Warsaw, , Poland
Wojskowy Instytut Medyczny
Warsaw, , Poland
Ajou University Hospital
Suwon, Gyeonggi-do, South Korea
Gachon University Gil Medical Center
Incheon, Korea, South Korea
Severance Hospital Yonsei University Health System
Seoul, , South Korea
Konkuk University Hospital
Seoul, , South Korea
Seoul St. Mary's Hospital
Seoul, , South Korea
Chungang University Hospital
Seoul, , South Korea
Hallym University of Medicine
Seoul, , South Korea
Hospital Germans Trias i Pujol
Barcelona, Badalona, Spain
Hospital De Fuenlabrada
Fuenlabrada, Madrid, Spain
Hospital Universitario Rey Juan Carlos
Móstoles, Madrid, Spain
Clinica Universitaria De Navarra
Pamplona, Navarre, Spain
Hospital General Universitario Alicante
Alicante, , Spain
Hospital Infanta Leonor
Madrid, , Spain
Hospital Universitario 12 de Octubre
Madrid, , Spain
Hospital Universitario La Paz
Madrid, , Spain
Centro de Especialidades Mollabao
Pontevedra, , Spain
CHUV Centre Hospitalier Universitaire Vaudois
Lausanne, Canton of Vaud, Switzerland
Inselspital Bern
Bern, , Switzerland
HUG-Hôpitaux Universitaires de Genève
Geneva, , Switzerland
Universitätsspital Zürich
Zurich, , Switzerland
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Katoh N, Takita Y, Isaka Y, Nishikawa A, Torisu-Itakura H, Saeki H. Pooled Safety Analysis of Baricitinib in Adult Participants with Atopic Dermatitis in the Japanese Subpopulation from Six Randomized Clinical Trials. Dermatol Ther (Heidelb). 2022 Dec;12(12):2765-2779. doi: 10.1007/s13555-022-00828-5. Epub 2022 Oct 18.
Silverberg JI, DeLozier A, Sun L, Thyssen JP, Kim B, Yosipovitch G, Nunes FP, Gugiu PC, Doll HA, Eichenfield LF. Psychometric properties of the itch numeric rating scale, skin pain numeric rating scale, and atopic dermatitis sleep scale in adult patients with moderate-to-severe atopic dermatitis. Health Qual Life Outcomes. 2021 Oct 23;19(1):247. doi: 10.1186/s12955-021-01877-8.
Thyssen JP, Buhl T, Fernandez-Penas P, Kabashima K, Chen S, Lu N, DeLozier AM, Casillas M, Stander S. Baricitinib Rapidly Improves Skin Pain Resulting in Improved Quality of Life for Patients with Atopic Dermatitis: Analyses from BREEZE-AD1, 2, and 7. Dermatol Ther (Heidelb). 2021 Oct;11(5):1599-1611. doi: 10.1007/s13555-021-00577-x. Epub 2021 Jul 18.
Buhl T, Rosmarin D, Serra-Baldrich E, Fernandez-Penas P, Igarashi A, Konstantinou MP, Chen S, Lu N, Pierce E, Casillas M. Itch and Sleep Improvements with Baricitinib in Patients with Atopic Dermatitis: A Post Hoc Analysis of 3 Phase 3 Studies. Dermatol Ther (Heidelb). 2021 Jun;11(3):971-982. doi: 10.1007/s13555-021-00534-8. Epub 2021 Apr 25.
King B, Maari C, Lain E, Silverberg JI, Issa M, Holzwarth K, Brinker D, Cardillo T, Nunes FP, Simpson EL. Extended Safety Analysis of Baricitinib 2 mg in Adult Patients with Atopic Dermatitis: An Integrated Analysis from Eight Randomized Clinical Trials. Am J Clin Dermatol. 2021 May;22(3):395-405. doi: 10.1007/s40257-021-00602-x. Epub 2021 Apr 7.
Reich K, DeLozier AM, Nunes FP, Thyssen JP, Eichenfield LF, Wollenberg A, Ross Terres JA, Watts SD, Chen YF, Simpson EL, Silverberg JI. Baricitinib improves symptoms in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids: patient-reported outcomes from two randomized monotherapy phase III trials. J Dermatolog Treat. 2022 May;33(3):1521-1530. doi: 10.1080/09546634.2020.1839008. Epub 2020 Nov 22.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol
Document Type: Statistical Analysis Plan
Related Links
Access external resources that provide additional context or updates about the study.
A Study of Baricitinib (LY3009104) in Adults With Moderate to Severe Atopic Dermatitis (Eczema) (BREEZE-AD2)
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
I4V-MC-JAHM
Identifier Type: OTHER
Identifier Source: secondary_id
2017-000871-10
Identifier Type: EUDRACT_NUMBER
Identifier Source: secondary_id
16581
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.